Bend Bioscience, a U.S.-based CDMO specializing in small-molecule drug development and manufacturing, has expanded its footprint in Oregon with four new GMP manufacturing and process development suites, enhancing its capabilities for complex oral solid dose and bioavailability-challenged molecules.

Additionally, the company’s investment in a ~12,000-square-foot expansion at its Georgia site will bring new commercial manufacturing capacity online — including spray drying scale-up, potent compound handling, and flexible scheduling to further support client needs.

Bend Bioscience says it is equally proud of its upcoming apprenticeship partnership with Lanier Technical College, part of its ongoing commitment to workforce development and local economic growth.

Bend Bioscience will be present at CPHI Worldwide in Frankfurt at Booth #5.1A49.